Patents by Inventor Giancarlo Trani
Giancarlo Trani has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240092773Abstract: The present invention relates to dihydro-cyclopenta-isoquinoline derivatives of formula (I): processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular, disorders caused by the interaction of IgE with the Fc?RI receptor.Type: ApplicationFiled: December 22, 2020Publication date: March 21, 2024Inventors: Timothy John NORMAN, Zhaoning ZHU, Selvaratnam SUGANTHAN, Konstantinos RAMPALAKO, James MADDEN, Jag Paul HEER, Richard Jeremy FRANKLIN, Rickki Lee CONNELLY, Thierry DEMAUDE, Gregory William HASLETT, Benedicte LALLEMAND, Nathaniel Julius Thomas MONCK, Julian Hugh ROWLEY, Giancarlo TRANI
-
Publication number: 20230303517Abstract: The present invention relates to dihydrocyclopenta-isoquinoline-sulfonamide derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the Fc?RI receptor.Type: ApplicationFiled: December 22, 2020Publication date: September 28, 2023Inventors: Timothy John NORMAN, Douglas BYRNE, Julian Hugh ROWLEY, Giancarlo TRANI, Konstantinos RAMPALAKOS, Nathaniel Julius Thomas MONCK, Benedicte LALLEMAND, Gregory William HASLETT, Rickki Lee CONNELLY, Jag Paul HEER, James MADDEN, Oliver PHILPS, Selvaratnam SUGANTHAN, Zeshan YOUSUF, Richard John MEARS
-
Publication number: 20230271951Abstract: A series of substituted 4,4-difluorocyclohexyl derivatives as defined herein, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.Type: ApplicationFiled: April 6, 2021Publication date: August 31, 2023Inventors: Prafulkumar Tulshibhai CHOVATIA, Anne Marie FOLEY, Gregory William HASLETT, Martin Clive HUTCHINGS, James Andrew JOHNSON, Fabien Claude LECOMTE, Nathaniel Julius Thomas MONCK, Joanna Rachel QUINCEY, Konstantinos RAMPALAKOS, James Thomas REUBERSON, Adam Peter SMALLEY, Giancarlo TRANI, Darshan Gunvant VAIDYA
-
Publication number: 20230051300Abstract: The present invention relates to tetrahydrobenzo-isoquinoline sulfonamides derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the FIERI receptor.Type: ApplicationFiled: December 22, 2020Publication date: February 16, 2023Inventors: Timothy John NORMAN, Oliver PHILPS, Gregory William HASLETT, Jag Paul HEER, Giancarlo TRANI
-
Publication number: 20220332709Abstract: Thiophene derivatives of formula (I) and a pharmaceutically acceptable salt thereof are provided. These compounds have utility for the treatment or prevention of disorders caused by IgE, such as allergy, type 1 hypersensitivity or familiar sinus inflammation.Type: ApplicationFiled: June 20, 2019Publication date: October 20, 2022Inventors: Pfrafulkumar Tulshibhai Chovatia, Rickki Lee Connelly, Richard Jeremy Franklin, Gregory William Haslett, Alistair James Henry, James Madden, Judi Charlotte Neuss, Timothy John Norman, Oliver Philps, William Ross Pitt, Konstantinos Rampalakos, Matthew Duncan Selby, Suganthan Selvaratnam, Giancarlo Trani, Zhaoning Zhu
-
Patent number: 10287299Abstract: A series of substituted 3,4-dihydro-2H-.1,4-benzoxazin-3-one derivatives, and analogs thereof, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neuradegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.Type: GrantFiled: June 7, 2016Date of Patent: May 14, 2019Assignee: UCB Biopharma SPRLInventors: Gareth Neil Brace, Prafulkumar Tulshibhai Chovatia, Gregory Foulkes, James Andrew Johnson, Severine Danielle Jones, Boris Kroeplien, Fabien Claude Lecomte, Pui Leng Loke, Martin Alexander Lowe, Ajay Mandal, Timothy John Norman, Christopher Francis Palmer, Yolanda Pérez-Fuertes, John Robert Porter, Donald Smyth, Giancarlo Trani, Muhammed Uddin, Zhaoning Zhu
-
Publication number: 20180134728Abstract: A series of substituted 3,4-di-hydro-2H-.1,4-benzoxazin-3-one derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.Type: ApplicationFiled: June 7, 2016Publication date: May 17, 2018Inventors: Gareth Neil Brace, Prafulkumar Tulshibhai Chovatia, Gregory Foulkes, James Andrew Johnson, Severine Danielle Jones, Boris Kroeplien, Fabien Claude Lecomte, Pui Leng Loke, Martin Alexander Lowe, Ajay Mandal, Timothy John Norman, Christopher Francis Palmer, Yolanda Pérez-Fuertes, John Robert Porter, Donald Smyth, Giancarlo Trani, Muhammed Uddin, Zhaoning Zhu
-
Patent number: 8513248Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein A is hydrogen, C1-4alkyl, C3-6cycloalkyl, C1-3alkoxy, C1-3alkoxy C1-4alkyl, C1-2fluoroalkyl, halogen, NR6R7, optionally substituted heteroaryl (Het), or optionally substituted phenyl, and R1, R2, R3, R4, R5, R6 and R7 are as defined in the description. The compounds or salts are thought to modulate P2X7 receptor function and to be capable of antagonizing the effects of ATP at the P2X7 receptor. The invention also provides the use of the compound or salt in the treatment or prophylaxis of, for example, inflammatory pain, neuropathic pain, visceral pain, rheumatoid arthritis or osteoarthritis or neurodegenerative disorders.Type: GrantFiled: April 28, 2010Date of Patent: August 20, 2013Assignee: Glaxo Group LimitedInventors: David Kenneth Dean, Jorge Munoz-Muriedas, Mairi Sime, Jon Graham Anthony Steadman, Rachel Elizabeth Anne Thewlis, Giancarlo Trani, Ian David Wall, Daryl Simon Walter
-
Patent number: 8501946Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein A is hydrogen, C1-4alkyl, C3-6cycloalkyl, C1-3alkoxy, C1-3alkoxy C1-4alkyl, C1-2fluoroalkyl, halogen, NR6R7, optionally substituted heteroaryl (Het), or optionally substituted phenyl, and R1, R2, R3, R4, R5, R6 and R7 are as defined in the description. The compounds or salts are thought to modulate P2X7 receptor function and to be capable of antagonizing the effects of ATP at the P2X7 receptor. The invention also provides the use of the compound or salt in the treatment or prophylaxis of, for example, inflammatory pain, neuropathic pain, visceral pain, rheumatoid arthritis, osteoarthritis or neurodegenerative disorders.Type: GrantFiled: April 28, 2010Date of Patent: August 6, 2013Assignee: Glaxo Group LimitedInventors: David Kenneth Dean, Jorge Munoz-Muriedas, Mairi Sime, Jon Graham Anthony Steadman, Rachel Elizabeth Anne Thewlis, Giancarlo Trani, Daryl Simon Walter
-
Publication number: 20120172366Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein A is hydrogen, C1-4alkyl, C3-6cycloalkyl, C1-3alkoxy, C1-3alkoxy C1-4alkyl, C1-2fluoroalkyl, halogen, NR6R7, optionally substituted heteroaryl, or optionally substituted phenyl, and R1, R2, R3, R4, R5, R6 and R7 are as defined in the description. The compounds or salts are thought to modulate P2X7 receptor function and to be capable of antagonizing the effects of ATP at the P2X7 receptor. The invention also provides the use of the compound or salt in the treatment or prophylaxis of, for example, inflammatory pain, neuropathic pain, visceral pain, rheumatoid arthritis or osteoarthritis or neurodegenerative disorders.Type: ApplicationFiled: April 28, 2010Publication date: July 5, 2012Inventors: David Kenneth Dean, Jorge Munoz-Muriedas, Mairi Sime, Jon Graham Anthony Steadman, Rachel Elizabeth Anne Thewlis, Giancarlo Trani, Ian David Wall, Daryl Simon Walter
-
Publication number: 20120157436Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein A is hydrogen, C1-4alkyl, C3-6cycloalkyl, C1-3alkoxy, C1-3alkoxy C1-4alkyl, C1-2-fluoroalkyl, halogen, NR6R7, optionally substituted heteroaryl, or optionally substituted phenyl, and R1, R2, R3, R4, R5, R6 and R7 are as defined in the description. The compounds or salts are thought to modulate P2X7 receptor function and to be capable of antagonizing the effects of ATP at the P2X7 receptor. The invention also provides the use of the compound or salt in the treatment or prophylaxis of, for example, inflammatory pain, neuropathic pain, visceral pain, rheumatoid arthritis, osteoarthritis or neurodegenerative disorders.Type: ApplicationFiled: April 28, 2010Publication date: June 21, 2012Inventors: David Kenneth Dean, Jorge Munoz-Muriedas, Mairi Sime, Jon Graham Anthony Steadman, Rachel Elizabeth Anne Thewlis, Giancarlo Trani, Daryl Simon Walter
-
Patent number: 7960563Abstract: The present invention relates to novel indazole derivatives having pharmacological activity, processes for their preparation, compositions containing them and uses of these compounds in the treatment of estrogen receptor beta mediated diseases.Type: GrantFiled: March 5, 2008Date of Patent: June 14, 2011Assignee: Glaxo Group LimitedInventors: Christopher Norbert Johnson, David G Jones, Xi Liang, David Timothy MacPherson, Aaron B Miller, Antoinette Naylor, Steven James Stanway, Andrew Kenneth Takle, Giancarlo Trani
-
Patent number: 7956083Abstract: The present invention relates to novel indole derivatives having pharmacological activity, processes for their preparation, compositions containing them and the use of these compounds in the treatment of estrogen receptor beta mediated diseases.Type: GrantFiled: February 17, 2009Date of Patent: June 7, 2011Assignee: Glaxo Group LimitedInventors: Christopher Norbert Johnson, David G. Jones, Xi Liang, David Timothy MacPherson, Aaron B Miller, Steven James Stanway, Andrew Kenneth Takle, Giancarlo Trani, Antoinette Wilson
-
Publication number: 20100324106Abstract: The present invention relates to novel indole derivatives having pharmacological activity, processes for their preparation, compositions containing them and the use of these compounds in the treatment of estrogen receptor beta mediated diseases.Type: ApplicationFiled: February 17, 2009Publication date: December 23, 2010Inventors: Christopher Norbert Johnson, David G. Jones, Xi Liang, David Timothy Macpherson, Aaron B. Miller, Steven James Stanway, Andrew Kenneth Takle, Giancarlo Trani, Antoinette Wilson
-
Publication number: 20100087502Abstract: The present invention relates to novel indazole derivatives having pharmacological activity, processes for their preparation, compositions containing them and uses of these compounds in the treatment of estrogen receptor beta mediated diseases.Type: ApplicationFiled: March 5, 2008Publication date: April 8, 2010Applicant: GLAXO GROUP LIMITEDInventors: Christopher Norbert Johnson, David G. Jones, Xi Liang, David Timothy Macpherson, Aaron B. Miller, Antoinette Naylor, Steven James Stanway, Andrew Kenneth Takle, Giancarlo Trani
-
Publication number: 20080058391Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof: wherein; each of R1 to R4 is independently selected from hydrogen and C1-4 alkyl and each of rings A and B independently is optionally further substituted by up to three substituents, each of which is independently selected from the group consisting of halogen, hydroxy, C1-4alkoxy, C1-4alkyl, C1-5alkanoyl, CF3, CF3O and cyano; with the proviso that ring A must contain at least one CF3 group, are useful in the treatment of diseases and conditions mediated by modulation of use-dependent voltage-gated sodium channels.Type: ApplicationFiled: August 8, 2007Publication date: March 6, 2008Applicant: GLAXO GROUP LIMITEDInventors: Christopher Johnson, David MacPherson, Giancarlo Trani
-
Publication number: 20070191345Abstract: The present invention relates to novel quinoline derivatives such as compounds of the formula (I): and the use of such compounds or pharmaceutical compositions thereof in the treatment of CNS and other disorders.Type: ApplicationFiled: March 24, 2005Publication date: August 16, 2007Applicant: GLAXO GROUP LIMITEDInventors: Mahmood Ahmed, Christopher Johnson, Neil Miller, Giancarlo Trani, David Witty